Unnamed: 0,title,date,stock,sentiment
402582.0,95 Biggest Movers From Yesterday,2020-06-09 05:06:00-04:00,EBS,neutral
402583.0,71 Stocks Moving In Monday's Mid-Day Session,2020-06-08 12:03:00-04:00,EBS,neutral
402584.0,"Cantor Fitzgerald Maintains Overweight on Emergent BioSolutions, Lowers Price Target to $85",2020-06-08 08:55:00-04:00,EBS,negative
402585.0,33 Stocks Moving in Monday's Pre-Market Session,2020-06-08 07:15:00-04:00,EBS,neutral
402586.0,"The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs",2020-06-02 07:45:00-04:00,EBS,negative
402587.0,Stocks That Hit 52-Week Highs On Monday,2020-06-01 10:41:00-04:00,EBS,neutral
402588.0,Emergent BioSolutions Wins a Task Order from the Department of Health & Human Services to Use its Manufacturing Infrastructure to Support the US Government's Delivery of Coronavirus Vaccines,2020-06-01 06:35:00-04:00,EBS,positive
402589.0,"The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter",2020-05-13 07:40:00-04:00,EBS,neutral
402590.0,Stocks That Hit 52-Week Highs On Tuesday,2020-05-12 10:41:00-04:00,EBS,neutral
402591.0,"The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings",2020-05-12 08:06:00-04:00,EBS,negative
402592.0,Stocks That Hit 52-Week Highs On Monday,2020-05-11 10:28:00-04:00,EBS,neutral
402593.0,"Argus Research Maintains Buy on Emergent BioSolutions, Raises Price Target to $90",2020-05-06 09:25:00-04:00,EBS,neutral
402594.0,"Cantor Fitzgerald Maintains Overweight on Emergent BioSolutions, Raises Price Target to $86",2020-05-01 10:00:00-04:00,EBS,negative
402595.0,"Chardan Capital Maintains Buy on Emergent BioSolutions, Raises Price Target to $86",2020-05-01 09:24:00-04:00,EBS,neutral
402596.0,"Moderna, Lonza Strike Deal To Manufacture Up To 1 Billion Doses Of Coronavirus Vaccine Candidate Annually",2020-05-01 09:11:00-04:00,EBS,negative
402597.0,Emergent BioSolutions Sees FY20 Sales Guidance Of $1.175B-$1.275B,2020-04-30 16:36:00-04:00,EBS,neutral
402598.0,"Emergent BioSolutions Q1 EPS $0.010, Inline, Sales $192.500M Miss $199.470M Estimate",2020-04-30 16:35:00-04:00,EBS,negative
402599.0,"Wells Fargo Maintains Overweight on Emergent BioSolutions, Raises Price Target to $85",2020-04-30 11:22:00-04:00,EBS,negative
402600.0,"The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Hologic To Launch Coronavirus Test, Amarin's Strong Q1",2020-04-30 07:19:00-04:00,EBS,positive
402601.0,Stocks That Hit 52-Week Highs On Monday,2020-04-27 10:21:00-04:00,EBS,neutral
402602.0,"The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight",2020-04-26 16:37:00-04:00,EBS,negative
402603.0,Stocks That Hit 52-Week Highs On Friday,2020-04-24 10:33:00-04:00,EBS,neutral
402604.0,"Novavax Identifies COVID-19 Vaccine Candidate, Human Testing To Begin In Mid-May",2020-04-08 10:12:00-04:00,EBS,neutral
402605.0,"The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO",2020-04-03 07:36:00-04:00,EBS,neutral
402606.0,Emergent BioSolutions Reports Partnership With US Gov't. For Comprehensive Response To Expedite Development Of Plasma-Derived Therapy For Coronavirus,2020-04-02 16:11:00-04:00,EBS,positive
402607.0,10 Biotech Winners And Losers In Q1,2020-04-01 16:35:00-04:00,EBS,negative
402608.0,"The Daily Biotech Pulse: InflaRx Begins Human Testing For COVID-induced Pneumonia, Chembio, Becton Dickinson Launch Coronavirus Tests",2020-04-01 07:38:00-04:00,EBS,neutral
402609.0,Emergent BioSolutions Signs Agreement With Novavax To Manufacture NanoFlu,2020-03-31 16:07:00-04:00,EBS,positive
402610.0,"Vaxart, Emergent Biosolutions Partner On Coronavirus Vaccine Development",2020-03-18 11:48:00-04:00,EBS,neutral
402611.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,EBS,positive
402612.0,Emergent BioSolutions and Vaxart shares are trading higher after the companies announced they have entered into an agreement for the development and manufacturing of the oral Coronavirus vaccine candidate.,2020-03-18 07:29:00-04:00,EBS,positive
402613.0,Vaxart Announces It Entered Into An Agreement With Emergent Biosolutions For The Development And Manufacturing Of Oral Coronavirus Vaccine Candidate,2020-03-18 06:32:00-04:00,EBS,positive
402614.0,Emergent BioSolutions CEO Talks Coronavirus Vaccine Development,2020-03-12 14:40:00-04:00,EBS,neutral
402615.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,EBS,negative
402616.0,Emergent BioSolutions Reports Initiation Of Development Of Plasma-Derived Product Candidates For Treatment Of Coronavirus,2020-03-11 16:22:00-04:00,EBS,neutral
402617.0,"Teladoc, Ping Identity, Emergent Biosolutions: Portfolio Manager Shares Stock Picks After Monday's Carnage",2020-03-10 11:20:00-04:00,EBS,positive
402618.0,Emergent BioSolutions Earlier Signs Development and Manufacturing Agreement With Novavax for Experimental Vaccine Candidate for Coronavirus Disease,2020-03-10 10:30:00-04:00,EBS,positive
402619.0,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index",2020-03-10 09:19:00-04:00,EBS,negative
402620.0,"Wells Fargo Maintains Overweight on Emergent BioSolutions, Raises Price Target to $75",2020-02-25 08:05:00-05:00,EBS,negative
402621.0,Stocks That Hit 52-Week Highs On Friday,2020-02-21 10:26:00-05:00,EBS,neutral
402622.0,Emergent BioSolutions Sees FY20 Sales $1.175B-$1.275B vs $1.23B Est.,2020-02-20 16:34:00-05:00,EBS,neutral
402623.0,"Emergent BioSolutions Q4 Adj. EPS $1.57 Misses $1.73 Estimate, Sales $360.4M Beat $358.7M Estimate",2020-02-20 16:34:00-05:00,EBS,negative
402624.0,"The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study",2020-02-20 07:06:00-05:00,EBS,negative
402625.0,"Earnings Scheduled For February 20, 2020",2020-02-20 04:17:00-05:00,EBS,neutral
402626.0,"The Week Ahead In Biotech: Baudax Bio, Merck, Esperion Await FDA Decisions",2020-02-16 15:03:00-05:00,EBS,positive
402627.0,Emergent BioSolutions Reports Receives Positive CHMP Opinion For Vaxchora; Sees Near-Term Approval By EMA,2020-01-31 09:32:00-05:00,EBS,positive
402628.0,Emergent Biosolutions Receives European Medicine Agency Approval to Pursue its Proposed Development Plan for Chikungunya,2020-01-13 07:37:00-05:00,EBS,positive
402629.0,Emergent BioSolutions Narrows FY2019 Sales Guidance from $1.06B-1.14B to $1.1B-1.105B vs $1.11B Est.,2020-01-13 06:46:00-05:00,EBS,neutral
402630.0,Emergent BioSolutions Highlights Presentation Of Immunogenicity Results From Phase 2 Study Of Investigational Chikungunya VLP Vaccine Candidate,2019-11-22 08:23:00-05:00,EBS,neutral
402631.0,"Emergent BioSolutions Q3 EPS $1.21 Beats $0.9 Estimate, Sales $311.8M Beat $289.27M Estimate",2019-11-06 16:28:00-05:00,EBS,neutral
402632.0,"The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings",2019-11-06 08:21:00-05:00,EBS,positive
402633.0,Emergent BioSolutions Reports Received European Medicines Agency Prime Designation For Chikungunya Virus Virus-Like Particle Vaccine Candidate,2019-10-10 06:46:00-04:00,EBS,neutral
402634.0,Emergent BioSolutions Reports Received $6.3M NIH Research Grant To Further Develop AP007 For Treatment for Opioid Use Disorder,2019-09-27 06:38:00-04:00,EBS,negative
402635.0,Emergent BioSolutions Wins $20M To Develop Diazepam Auto-Injector To Treat Nerve Agent-Induced Seizures For US Department Of Defense,2019-09-25 16:16:00-04:00,EBS,positive
402636.0,"Benzinga's Top Upgrades, Downgrades For September 12, 2019",2019-09-12 09:32:00-04:00,EBS,positive
402637.0,"Guggenheim Initiates Coverage On Emergent BioSolutions with Buy Rating, Announces $65 Price Target",2019-09-12 07:21:00-04:00,EBS,neutral
402638.0,60 Biggest Movers From Yesterday,2019-09-05 05:20:00-04:00,EBS,neutral
402639.0,Wells Fargo Upgrades Emergent Biosolutions After Smallpox Vaccine Announcement,2019-09-04 12:25:00-04:00,EBS,positive
402640.0,"Benzinga's Top Upgrades, Downgrades For September 4, 2019",2019-09-04 11:01:00-04:00,EBS,positive
402641.0,"Wells Fargo Upgrades Emergent BioSolutions to Outperform, Raises Price Target to $64",2019-09-04 06:17:00-04:00,EBS,positive
402642.0,66 Biggest Movers From Yesterday,2019-09-04 05:07:00-04:00,EBS,neutral
402643.0,44 Stocks Moving In Tuesday's Mid-Day Session,2019-09-03 12:34:00-04:00,EBS,neutral
402644.0,Mid-Morning Market Update: Markets Open Lower; Conn's Beats Q2 Expectations,2019-09-03 10:22:00-04:00,EBS,negative
402645.0,Emergent BioSolutions Awarded 10-Year HHS Contract To Deliver ACAM2000 Smallpox Vaccine To US Strategic National Stockpile,2019-09-03 06:34:00-04:00,EBS,positive
402646.0,"Emergent BioSolutions Q2 EPS $(0.18) May Not Compare To $0.17 Estimate, Sales $243.2M Beat $212.06M Estimate",2019-08-01 16:09:00-04:00,EBS,neutral
402647.0,"The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings",2019-08-01 07:18:00-04:00,EBS,negative
402648.0,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",2019-07-27 14:32:00-04:00,EBS,negative
402649.0,Shares of several drug manufacturing companies are trading lower. The Trump Administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices.,2019-07-11 10:36:00-04:00,EBS,negative
402650.0,"Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.",2019-07-08 12:55:00-04:00,EBS,positive
402651.0,Many US-traded stocks are trading higher as new economic signals have raised the potential for a Federal Reserve rate cut.,2019-06-07 15:33:00-04:00,EBS,negative
402652.0,"Emergent BioSolutions Reports FDA Approval Of Change In Storage Conditions, Transfer Of Manufacturing for Cholera Vaccine",2019-06-04 16:25:00-04:00,EBS,positive
402653.0,Emergent BioSolutions Announces FDA Approval Af Change In Storage Conditions And Transfer Of Manufacturing For Its Cholera Vaccine,2019-06-04 16:10:00-04:00,EBS,positive
402654.0,"Shares of several biotechs are trading higher in sympathy with Amgen after the company presented the first clinical data evaluating a KRASG12C inhibitor, AMG 510, at ASCO 2019.",2019-06-03 09:32:00-04:00,EBS,positive
402655.0,A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street,2019-06-03 07:17:00-04:00,EBS,negative
402656.0,Emergent BioSolutions Wins a $35M Contract from the US Department of Health and Human Services,2019-06-03 06:33:00-04:00,EBS,positive
402657.0,"The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering",2019-05-31 07:34:00-04:00,EBS,positive
402658.0,"The Daily Biotech Pulse: Unity Biotech Licenses Anti-Aging Protein, Strong Results For Mereo's Brittle Bone Disease Drug",2019-05-30 07:33:00-04:00,EBS,positive
402659.0,"The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails",2019-05-21 07:40:00-04:00,EBS,negative
402660.0,Emergent BioSolutions Reports 5 EU Countries Have Granted Marketing Authorization For Oral Typhoid Vaccine,2019-05-20 16:41:00-04:00,EBS,positive
402661.0,Emergent BioSolutions Reports Prepared For Initial Shipments Of AV7909 Anthrax Vaccine Candidate Into Strategic National Stockpile,2019-05-15 18:01:00-04:00,EBS,positive
402662.0,"The Daily Biotech Pulse: Further Delay in Roche's Spark Acquisition, FDA Nod For Regeneron, Solid Biosciences Sinks On Earnings",2019-05-14 07:42:00-04:00,EBS,positive
402663.0,"The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales",2019-05-10 08:00:00-04:00,EBS,negative
402664.0,"The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split",2019-05-08 07:53:00-04:00,EBS,negative
402665.0,Emergent BioSolutions shares are trading lower after the company reported worse-than-expected Q1 EPS and sales results.,2019-05-03 13:49:00-04:00,EBS,neutral
402666.0,"Emergent BioSolutions Q1 Adj. EPS $(0.13) Misses $0.09 Estimate, Sales $190.6M Miss $201.16M Estimate",2019-05-02 17:00:00-04:00,EBS,negative
402667.0,"The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data",2019-05-02 08:16:00-04:00,EBS,positive
402668.0,"Emergent BioSolutions Says Interim Analysis Of Phase 2 Of CHIKV-VLP, A Chikungunya Virus Vaccine Candidate, Neutralized Antibody Response In 98% Of Patients",2019-04-16 06:34:00-04:00,EBS,neutral
402669.0,Emergent BioSolutions Initiates Phase 3 Clinical Study To Evaluate AV7909 For Post-Exposure Prophylaxis Of Anthrax,2019-03-19 06:30:00-04:00,EBS,neutral
402670.0,"Emergent Biosolutions Shares Rebound From Session Low, Hearing Cantor Fitzgerald Sees News By Purdue Pharma A Nonevent For Co., Will Have No Effect On Narcan",2019-03-13 10:42:00-04:00,EBS,negative
402671.0,"Emergent Biosciences Wins Us Dept. Of State Contract To Supply Medical Countermeasures For Chemical Warfare Agents, Comprised Of 5-Year Base For Minimum Of $7M To Maximum $100M",2019-02-28 17:07:00-05:00,EBS,positive
402672.0,"Emergent BioSolutions Q4 EPS $0.75 Beats $0.62 Estimate, Sales $270.7M Beat $270.4M Estimate",2019-02-21 16:57:00-05:00,EBS,neutral
402673.0,Emergent BioSolutions Sees FY2019 Sales $1.06B-1.14B vs $1.02B Est,2019-01-07 06:33:00-05:00,EBS,neutral
402674.0,Emergent BioSolutions Narrows FY2018 Sales Guidance from $770.0M-800.0M to $779.0M-784.0M vs $778.95M Est,2019-01-07 06:33:00-05:00,EBS,neutral
402675.0,Emergent BioSolutions Reports Submission To FDA Of Its Application Covering Emergency Use Authorization For NuThrax,2018-12-28 09:01:00-05:00,EBS,negative
402676.0,Watching Emergent Biosolutions Shares; Hearing FDA Panel Has Voted 12-11 To Recommend Co-Prescribing Of Naloxone For Patients With Prescribed Opioids,2018-12-18 15:19:00-05:00,EBS,positive
402677.0,Emergent BioSolutions Reports Received Health Canada Approval Of BioThrax,2018-12-17 16:10:00-05:00,EBS,positive
402678.0,"Stocks Which Set New 52-Week High Yesterday, Mon., Dec. 3, 2018",2018-12-04 09:20:00-05:00,EBS,neutral
402679.0,"The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO",2018-12-04 07:59:00-05:00,EBS,neutral
402680.0,"Stocks Which Set New 52-Week High Yesterday, Thurs., Nov. 29, 2018",2018-11-30 10:25:00-05:00,EBS,neutral
402681.0,"The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings",2018-11-30 08:25:00-05:00,EBS,negative
402682.0,"Stocks Which Set New 52-Week High Yesterday, Wed., Nov. 28, 2018",2018-11-29 10:49:00-05:00,EBS,neutral
402683.0,"Stocks Which Set New 52-Week High Yesterday, Mon., Nov. 26, 2018",2018-11-27 11:25:00-05:00,EBS,neutral
402684.0,"The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial",2018-11-27 07:32:00-05:00,EBS,negative
402685.0,"Stocks Which Set New 52-Week High The Prior Trading Session, Fri., Nov. 23, 2018",2018-11-26 10:44:00-05:00,EBS,neutral
402686.0,"Emergent Biosolutions, Valneva Report Phase 1 Results For Vaccine Candidate Against Zika: Met Primary Endpoint For Safety",2018-11-19 16:20:00-05:00,EBS,positive
402687.0,"Stocks Which Set New 52-Week High Yesterday, Wed., Nov. 7, 2018",2018-11-08 10:52:00-05:00,EBS,neutral
402688.0,"The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering",2018-11-08 08:10:00-05:00,EBS,negative
402689.0,10 Biggest Price Target Changes For Friday,2018-11-02 09:43:00-04:00,EBS,neutral
402690.0,"Goldman Sachs Upgrades Emergent BioSolutions to Buy, Raises Price Target to $75",2018-11-02 07:21:00-04:00,EBS,neutral
402691.0,"Emergent Biosolutions Raises FY18 Sales Guidance From $715M-$755M To $770M-$800M, Adj. Net Income $110M-$125M To $105M-$115M",2018-11-01 16:56:00-04:00,EBS,neutral
402692.0,"Emergent Biosolutions, Inc. Q3 EPS $0.55 Misses $0.58 Estimate, Sales $173.653M Miss $184.1M Estimate",2018-11-01 16:55:00-04:00,EBS,negative
402693.0,"The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal",2018-11-01 07:30:00-04:00,EBS,negative
402694.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs",2018-10-27 10:23:00-04:00,EBS,neutral
402695.0,"UPDATE: Emergent Notes Co.'s Adapt Units, Opiant Pharma, On Oct. 25, 2018, Filed Complaint For Patent Infringement Against Perrigo In US Related To Perrigo's ANDA Filing With FDA",2018-10-25 09:49:00-04:00,EBS,negative
402696.0,Emergent BioSolutions 8-K Shows Adapt Pharma Received Notice From Perrigo UK FINCO That Perrigo Filed Abbreviated New Drug Application Seeking Approval To Market Generic Version Of NARCAN Nasal Spray,2018-10-25 09:48:00-04:00,EBS,positive
402697.0,"The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker",2018-10-05 08:35:00-04:00,EBS,positive
402698.0,"The Daily Biotech Pulse: Exelixis Liver Cancer Drug On Track For European Approval, Medtronic Goes Shopping, Opiant Snags BARDA Funding",2018-09-21 08:51:00-04:00,EBS,negative
402699.0,"Stocks Which Set New 52-Week High Yesterday, September 20th",2018-09-21 08:16:00-04:00,EBS,neutral
402700.0,"Stocks Which Set New 52-Week High Yesterday, September 19th",2018-09-20 11:24:00-04:00,EBS,neutral
402701.0,"The Daily Biotech Pulse: Adverum Snags Fast Track Designation, Crispr To Offer Shares, Elanco Animal Health To Debut",2018-09-20 09:02:00-04:00,EBS,positive
402702.0,"The Daily Biotech Pulse: Johnson & Johnson's Generic Unit Files NDA For Urinary Tract Cancer Drug, G1 Therapeutics Prices Offering",2018-09-19 08:47:00-04:00,EBS,negative
402703.0,"Stocks Which Set New 52-Week High Yesterday, September 17th",2018-09-18 09:25:00-04:00,EBS,neutral
402704.0,"The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares",2018-09-18 08:44:00-04:00,EBS,positive
402705.0,"Stocks Which Set New 52-Week High Friday, September 14th",2018-09-17 09:28:00-04:00,EBS,neutral
402706.0,"Stocks Which Set New 52-Week High Yesterday, August 30th",2018-08-31 10:11:00-04:00,EBS,neutral
402707.0,"The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage",2018-08-31 08:29:00-04:00,EBS,positive
402708.0,"Stocks Which Set New 52-Week High Yesterday, August 29th",2018-08-30 11:47:00-04:00,EBS,neutral
402709.0,"The Daily Biotech Pulse: Verastem Gets New CFO, Mesoblast Earnings, Vertex's Precision Medicine Collaboration",2018-08-30 08:02:00-04:00,EBS,neutral
402710.0,"Stocks Which Set New 52-Week High Yesterday, August 28th",2018-08-29 11:13:00-04:00,EBS,neutral
402711.0,"Opiant Pharmaceuticals Shares Up 81% Premarket Following Tuesday's After Hours News Its Commercial Partner, Adapt Pharma, To Be Acquired By Emergent Biosolutions For $735M",2018-08-29 09:29:00-04:00,EBS,positive
402712.0,"The Daily Biotech Pulse: Assertio Settles With Purdue, Emergent Biosolutions In M&A Mix, Novartis Eye Care Unit Recalls Stent",2018-08-29 07:54:00-04:00,EBS,positive
402713.0,UPDATE: Emergent To Acquire Adapt Pharma For $735M Total Consideration Consisting Of Upfront Payment Of $635M And Up To $100M In Cash For Potential Sales-Based Milestones; Upfront Payment Includes $575M In Cash And $60M Emergent Common Stock,2018-08-28 16:35:00-04:00,EBS,neutral
402714.0,UPDATE: Emergent Biosolutions Expects To Generate Rev. Of $200-$220M And For Acquisition Of Adapt Pharma To Be Accretive To Adj. Net Income And EBITDA In 2019,2018-08-28 16:34:00-04:00,EBS,neutral
402715.0,Emergent Biosolutions Acquires Adapt Pharma And NARCAN Nasal Spray For Total Consideration Of $735M,2018-08-28 16:32:00-04:00,EBS,neutral
402716.0,"The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetraphase's Antibiotic",2018-08-28 08:13:00-04:00,EBS,neutral
402717.0,"Stocks Which Set New 52-Week High Friday, August 24th",2018-08-27 09:24:00-04:00,EBS,neutral
402718.0,"Stocks Which Set New 52-Week High Yesterday, August 23rd",2018-08-24 09:11:00-04:00,EBS,neutral
402719.0,"The Daily Biotech Pulse: Immunomedics' Bottom-Line Miss; Kala, Regeneron Await FDA Verdict",2018-08-24 08:47:00-04:00,EBS,positive
402720.0,"Stocks Which Set New 52-Week High Yesterday, August 22nd",2018-08-23 10:51:00-04:00,EBS,neutral
402721.0,"The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero",2018-08-23 08:23:00-04:00,EBS,negative
402722.0,"Stocks Which Set New 52-Week High Yesterday, August 21st",2018-08-22 09:06:00-04:00,EBS,neutral
402723.0,"The Daily Biotech Pulse: FDA Snub For Allergan, Myriad's Q4 Beat, Mallinckrodt's Stannsoporfin",2018-08-22 08:20:00-04:00,EBS,negative
402724.0,"Stocks Which Set New 52-Week High Tues., Aug. 21, 2018",2018-08-21 14:50:00-04:00,EBS,neutral
402725.0,Emergent BioSolutions Announces Collaboration With Profectus BioSciences; The Companies Will Receive Up To $36M Contract From CEPI To Develop Lassa Virus Vaccine,2018-08-16 06:17:00-04:00,EBS,neutral
402726.0,Shares Of Emergent Biodefense Volatile As Traders Circulate An Earlier CDC FedBizOpps Document Showing The Purchase Of 9M Doses Of ACAM2000 Smallpox Vaccine,2018-08-15 12:48:00-04:00,EBS,positive
402727.0,Emergent BioSolutions Reports Purchase Of PaxVax For $270M In Cash,2018-08-09 06:46:00-04:00,EBS,neutral
402728.0,"Stocks Which Set New 52-Week Highs Friday, August 3rd",2018-08-06 13:02:00-04:00,EBS,neutral
402729.0,"Emergent Biosolutions Filing Shows Registration For Mixed Securities Shelf Offering, No Terms Disclosed",2018-08-03 06:18:00-04:00,EBS,neutral
402730.0,Emergent BioSolutions Sees Q3 Sales $165M-$190M vs $201.89M Est.,2018-08-02 16:33:00-04:00,EBS,neutral
402731.0,"Emergent BioSolutions Q2 Adj. EPS $1.07 Beats $0.88 Estimate, Sales $220.2M Beat $208.57M Estimate",2018-08-02 16:33:00-04:00,EBS,neutral
402732.0,"The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter",2018-08-02 08:54:00-04:00,EBS,positive
402733.0,"Emergent BioSolutions Reports Initiation Of Phase 1 Clinical Study To Evaluate Safety, Pharmacokinetics Of ZIKV-IG",2018-07-31 16:35:00-04:00,EBS,positive
402734.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-07-28 14:04:00-04:00,EBS,neutral
402735.0,"Benzinga's Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid Addiction Drug",2018-06-15 09:13:00-04:00,EBS,neutral
402736.0,Argus: Anthrax Vaccine Maker Emergent BioSolutions Poised For Earnings Growth,2018-06-13 10:51:00-04:00,EBS,positive
402737.0,"Benzinga's Top Upgrades, Downgrades For June 13, 2018",2018-06-13 09:19:00-04:00,EBS,positive
402738.0,"Argus Initiates Coverage On Emergent BioSolutions with Buy Rating, Announces $62 Price Target",2018-06-13 08:04:00-04:00,EBS,neutral
402739.0,"Cantor Fitzgerald Initiates Coverage On 8 Pharma/Biotech Stocks After Hours: 7 With Overweight, 1 With Neutral Rating",2018-06-11 16:54:00-04:00,EBS,negative
402740.0,Emergent BioSolutions Announces $50 Million Expansion Of Baltimore Fill/Finish Facility To Support Growth Of Contract Development And Manufacturing Capabilities,2018-06-07 06:31:00-04:00,EBS,positive
402741.0,"Emergent BioSolutions Reports $25M Collaboration With Profectus Biosciences, The Coalition For Epidemic Preparedness Innovations To Advance The Development, Manufacture Of Vaccine Against Nipah Virus",2018-05-24 06:14:00-04:00,EBS,neutral
402742.0,Emergent BioSolutions Sees FY2018 Sales $715.0M-755.0M vs $731.40M Est,2018-05-03 16:45:00-04:00,EBS,neutral
402743.0,"Emergent BioSolutions Q1 EPS $(0.03) Misses $0.20 Estimate, Sales $117.8M Miss $140.42M Estimate",2018-05-03 16:45:00-04:00,EBS,negative
402744.0,"Emergent Biosolutions' Stock Run Can't Continue Forever, Wells Fargo Says In Downgrade",2018-04-25 15:38:00-04:00,EBS,negative
402745.0,"Benzinga's Top Upgrades, Downgrades For April 25, 2018",2018-04-25 09:36:00-04:00,EBS,positive
402746.0,Wells Fargo Downgrades Emergent BioSolutions to Market Perform,2018-04-25 07:54:00-04:00,EBS,positive
402747.0,Emergent BioSolutions Reports Successful Completion Of Mutual Recognition Procedure For Market Authorization Of BioThrax In Europe,2018-04-12 06:32:00-04:00,EBS,positive
402748.0,Emergent BioSolutions Announces $50M Buyback,2018-03-22 16:37:00-04:00,EBS,neutral
402749.0,"Emergent BioSolutions Reports Winning Of 1-Year CDC Contract For Vaccinia Immune Globulin Program, Valued At $26M",2018-02-28 06:45:00-05:00,EBS,positive
402750.0,"UPDATE: Emergent BioSolutions Sees FY2020 Sales $1B, Profit Margin 14%+",2018-02-22 16:58:00-05:00,EBS,positive
402751.0,"Emergent BioSolutions Sees Q1 Sales Outlook Cut From $145M-$160M to $125M-$150M; FY18 Adj. Net Income $110M-$125M, Sales $715M-$755M vs $706.01M Est.",2018-02-22 16:58:00-05:00,EBS,negative
402752.0,"Emergent BioSolutions Reports Q4 Adj. EPS $0.67 vs $0.70 Est., Sales $193.8M vs $188.95M Est.",2018-02-22 16:55:00-05:00,EBS,neutral
402753.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-02-19 10:50:00-05:00,EBS,neutral
402754.0,"Goldman Sachs Initiates Coverage On Emergent BioSolutions with Neutral Rating, Announces $55.00 Price Target",2018-01-24 08:28:00-05:00,EBS,neutral
402755.0,"Emergent BioSolutions Narrows, Raises FY17 Sales Guidance From $540M-$560M To $555-$560M, Adj. Net Income From $85M-$95M To $92-$96M",2018-01-08 06:33:00-05:00,EBS,neutral
402756.0,"Emergent BioSolutions Begins Phase 2 Clinical Study to Evaluate FLU-IGIV, Phase 2 Study To Enroll ~75 Patients",2018-01-04 07:02:00-05:00,EBS,neutral
402757.0,Emergent BioSolutions Wins a Contract from the Canadian Department of National Defense for $8M to Supply Anthrasil,2017-12-12 07:08:00-05:00,EBS,positive
402758.0,4 Biotech Stocks To Better Your Financial Health This Winter,2017-12-04 12:25:00-05:00,EBS,positive
402759.0,"Emergent BioSolutions Announces FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility",2017-11-20 07:13:00-05:00,EBS,positive
402760.0,Emergent BioSolutions Increases FY17 Sales From $500-$530M To $540-$560M,2017-11-02 17:11:00-04:00,EBS,neutral
402761.0,"Emergent BioSolutions Reports Q3 EPS $0.68 vs $0.41 Est., Sales $149.43M vs $124.55M Est.",2017-11-02 17:09:00-04:00,EBS,neutral
402762.0,Emergent BioSolutions Wins $25M Contract with the US Department of State,2017-10-04 07:01:00-04:00,EBS,positive
402763.0,Emergent BioSolutions Wins $171M Department of Defense Contract Related to Chemical Threat,2017-09-25 07:04:00-04:00,EBS,positive
402764.0,Emergent Biosolutions Awarded $63M BARDA Contract,2017-09-18 08:02:00-04:00,EBS,positive
402765.0,"Emergent BioSolutions Reports Q2 Adj. Net Income $6.6M, Sales $100.8M vs $111.6M Est.",2017-08-03 17:29:00-04:00,EBS,neutral
402766.0,Emergent BioSolutions Reports Winning Of $23M Contract To Develop Novel Multi-Drug Auto-Injector For US Dept. Of Defense,2017-07-31 16:17:00-04:00,EBS,positive
402767.0,Emergent BioSolutions Reports Securing Of Exclusive Global Rights To Valneva's Zika Vaccine Technology,2017-07-26 16:50:00-04:00,EBS,positive
402768.0,"UPDATE: Emergent BioSoultions Deal For Raxibacumab Will Include $76M Upfront Cash Payment, $20M In Product Sale, Manufacturing-Related Milestone Payments",2017-07-19 16:21:00-04:00,EBS,neutral
402769.0,Emergent BioSolutions Reports Will Buy Raxibacumab From GSK For ~$130M,2017-07-19 16:20:00-04:00,EBS,neutral
402770.0,Emergent BioSolutions Reports Purchase Of ACAM2000 Unit From Sanofi For ~$125M In Cash,2017-07-14 07:01:00-04:00,EBS,neutral
402772.0,Emergent BioSolutions Q2 Sales $100-$115M vs $122M Est.,2017-05-04 17:10:00-04:00,EBS,neutral
402773.0,"Emergent BioSolutions Reports Q1 EPS $0.23 vs $0.30 Est., Sales $116.85M vs $116M Est",2017-05-04 17:10:00-04:00,EBS,neutral
402774.0,Anthrax And Government Contracts: PharmAthene And Altimmune Ahead Of Merger,2017-04-06 16:01:00-04:00,EBS,neutral
402775.0,Emergent BioSolutions Reports Winning of $100M BARDA Contract for BioThrax Delivieries to Strategic National Stockpile,2017-03-17 07:01:00-04:00,EBS,positive
402776.0,"Emergent BioSolutions Reports Q4 Adj. EPS $0.74 vs $0.48 Est., Sales $151.663M vs $120.45M Est.",2017-02-23 17:06:00-05:00,EBS,neutral
402777.0,Aptevo Therapeutics Receives $20M Payment From Emergent Biosolutions,2017-01-13 09:05:00-05:00,EBS,neutral
402778.0,"Emergent BioSolutions Reports Prelim FY16 Rev. $480-$485M, EBITDA $131-$135M; Sees FY17 Rev. $500-$530M",2017-01-09 07:03:00-05:00,EBS,neutral
402779.0,"Soligenix, Emergent Biosolutions Continue Development Agreement With NIAID Contract Funding Up To $24.7M",2017-01-03 07:04:00-05:00,EBS,positive
402780.0,Emergent BioSolutions Receives Health Canada Approval for Botulism Antitoxin,2016-12-12 07:03:00-05:00,EBS,positive
402781.0,Mid-Afternon Market Update: Restoration Hardware Tumbles On Weak Guidance; Stillwater Mining Shares Spike Higher,2016-12-09 14:36:00-05:00,EBS,negative
402782.0,Mid-Morning Market Update: Markets Open Higher; Finisar Beats Q2 Estimates,2016-12-09 10:07:00-05:00,EBS,neutral
402783.0,"UPDATE: Emergent Sees FY16 Sales on Continuing Operations Basis $465M-$485M vs $459M Est., EBITDA $120M-$130M",2016-12-08 17:16:00-05:00,EBS,neutral
402784.0,Emergent Biosolutions Reports Will Support HHS Anthrax Preparedness Strategy with Up to $1B in BioThrax Deliveries to Strategic National Stockpile,2016-12-08 17:14:00-05:00,EBS,positive
402785.0,"Emergent BioSolutions Reports Q3 EPS $0.58 vs. Prior Year Quarter $0.93, Rev. $142.9M",2016-11-07 16:27:00-05:00,EBS,neutral
402786.0,"Emergent Biosolutions Shares Up 13% on Heavy Volume; Co. Earlier Offered Update on Status of BioThrax Procurement contract, Discussions with CDC",2016-09-30 12:38:00-04:00,EBS,positive
402787.0,Emergent BioSolutions Receives FDA Approval for Large-Scale Manufacturing of BioThrax in Building 55,2016-08-15 16:25:00-04:00,EBS,positive
402788.0,"Emergent Biosolutions Reports Q2 Adj. EPS $(0.18) vs $(0.17) Est., Sales $101.5M vs $111.2M Est.",2016-08-04 17:16:00-04:00,EBS,neutral
402789.0,Emergent BioSolutions Spinoff Aptevo To Begin Trading Today Under Ticker APVO,2016-07-20 07:05:00-04:00,EBS,neutral
402790.0,Emergent BioSolutions To Implement $50 Million Share Buyback Program,2016-07-15 13:27:00-04:00,EBS,positive
402791.0,Emergent BioSolutions Announces $50M Buyback,2016-07-15 07:00:00-04:00,EBS,neutral
402792.0,Emergent BioSolutions Receives BARDA Order Up to $21.9 Million to Develop and Manufacture a Zika Vaccine,2016-06-27 09:00:00-04:00,EBS,neutral
402793.0,"JP Morgan On Emergenct BioSolutions: HHS Update Driving Quicker-Than-Anticipated Transition To Next-Gen Vaccine, Negative Outlooks On Estimates For BioThrax In 2017",2016-06-22 13:36:00-04:00,EBS,negative
402794.0,10 Biggest Mid-Day Losers For Wednesday,2016-06-22 13:17:00-04:00,EBS,negative
402795.0,Hearing Wells Fargo Defending Emergent Biosolutions Inc,2016-06-22 11:58:00-04:00,EBS,positive
402796.0,Emergent BioSolutions Says FDA Accepts Its sBLA For Large-Scale Manufacturing Of BioThrax In Building 55,2016-06-17 07:51:00-04:00,EBS,positive
402797.0,FDA Accepts Emergent BioSolutions' Supplemental Biologics License Application for Large-Scale Manufacturing of BioThrax in Building 55,2016-06-17 07:00:00-04:00,EBS,positive
402798.0,Emergent Biosolutions Reports FDA Orphan Drug Designation for BioThrax for Post-Exposure Prophylaxis of Anthrax Disease,2016-06-15 07:04:00-04:00,EBS,neutral
402799.0,"Emergent BioSolutions Reports Q1 EPS $0.16 vs. Est. $(0.07), Rev. $111M vs. Est. $101.8M",2016-05-05 16:27:00-04:00,EBS,neutral
402800.0,Emergent Biosolutions Reveals sBLA Submission To FDA To Make BioThrax In Building 55,2016-04-18 07:48:00-04:00,EBS,neutral
402801.0,Emergent BioSolutions Submits sBLA for FDA Approval of Large-Scale Manufacturing of BioThrax in Building 55,2016-04-18 07:02:00-04:00,EBS,positive
402802.0,"Chardan Capital Initiates Coverage on Emergent BioSolutions at Buy, Announces $47.00 PT",2016-04-15 05:57:00-04:00,EBS,neutral
402803.0,"Singular Research Initiates Coverage on Emergent BioSolutions at Buy, Announces $44.00 PT",2016-03-28 14:44:00-04:00,EBS,neutral
402804.0,"Emergent BioSolutions Sees Q1 Rev. $105-$120M vs. Est. $94M, FY16 Rev. $600-$630M vs. Est. $582M",2016-02-25 16:21:00-05:00,EBS,neutral
402805.0,"Emergent BioSolutions Reports Q4 EPS $0.78 vs. Est. $0.70, Rev. $168.1M vs. Est. $168M",2016-02-25 16:20:00-05:00,EBS,neutral
402806.0,Wells Fargo Initiates Coverage on Emergent BioSolutions at Outperform,2016-02-19 08:40:00-05:00,EBS,positive
402807.0,"Emergent BioSolutions Reports Co.'s Emergard Platform for Nerve Agent Antidote Delivery Has Been Choosen by Us Dept. of Defense and Battelle for Testing, Development",2016-02-17 07:08:00-05:00,EBS,positive
402808.0,Ligand Reports OmniAb Platform Licensing Deal with Emergent BioSolutions,2016-01-13 09:45:00-05:00,EBS,neutral
402809.0,"Emergent Biosolutions Releases Preliminary 2015 Results, 2016 Outlook And Strategic Growth Plan Through 2020",2016-01-11 09:15:00-05:00,EBS,positive
402810.0,Emergent BioSolutions Sees FY2016 Sales $600.0M-630.0M vs $544.32M Est,2016-01-11 07:11:00-05:00,EBS,neutral
402811.0,Emergent BioSolutions Sees Q1 Sales $105.0M-120.0M vs $83.0M Est,2016-01-11 07:03:00-05:00,EBS,neutral
402812.0,Emergent BioSolutions Sees FY2015 EPS $1.54-1.63 vs $1.51 Est; Sees Sales $520.0M-525.0M vs $524.80M Est,2016-01-11 07:02:00-05:00,EBS,neutral
402813.0,Emergent BioSolutions Announces Favorable IRS Private Letter Ruling Regarding Biosciences Business Spin-Off,2016-01-10 18:11:00-05:00,EBS,positive
402814.0,Emergent BioSolutions Announces Composition of Board of Directors of New Spin-Off Company Aptevo Therapeutics,2015-12-22 16:02:00-05:00,EBS,neutral
402815.0,FDA Approves Emergent BioSolutions' BioThrax for Post-Exposure Prophylaxis,2015-11-24 16:03:00-05:00,EBS,positive
402816.0,FDA Approves New Indication for BioThrax -DJ,2015-11-23 17:16:00-05:00,EBS,positive
402817.0,"Emergent Biosolutions Q3 EPS $0.79 Vs Est $0.55, Sales $164.9M Vs Est $151.42M",2015-11-05 16:39:00-05:00,EBS,neutral
402818.0,Cowen: In Biotech Earnings We Trust,2015-10-19 10:02:00-04:00,EBS,positive
402819.0,Emergent BioSolutions Receives $44M CDC Contract to Further Advance Vaccinia Immune Globulin Intravenous Program,2015-08-13 07:03:00-04:00,EBS,positive
402820.0,"Emergent Biosolutions Reports Q2 EPS $0.36 vs. Est. $0.18, Rev. $126.1M vs. Est. $114.25M",2015-08-06 07:13:00-04:00,EBS,neutral
402821.0,Emergent BioSolutions to Spin-Off of Biosciences Business Into Separate Publicly-Traded Company in Tax-Free Transaction,2015-08-06 07:11:00-04:00,EBS,neutral
402822.0,UPDATE: Emergent Biosolutions Announces $19.7M Contract,2015-07-20 07:15:00-04:00,EBS,neutral
402823.0,Emergent Biosolutions Announces $19.7M Contract,2015-07-20 07:02:00-04:00,EBS,neutral
402824.0,"Emergent BioSolutions Awarded $19.7 Million BARDA Contract to Develop, Manufacture Ebola Monoclonal Antibodies",2015-07-20 07:01:00-04:00,EBS,positive
402825.0,Pentagon Says Britain Added to List of Countries With Labs That Received Live Anthrax from US Military -Reuters,2015-06-09 11:44:00-04:00,EBS,neutral
402826.0,US Military Discovers Another Shipment of Live Anthrax from  2008 Batch Sent to Australia -Reuters,2015-05-29 11:11:00-04:00,EBS,neutral
402827.0,US Stock Futures Down Ahead Of Jobless Claims,2015-05-28 08:05:00-04:00,EBS,neutral
402828.0,"ProMetic Life Science to Acquire Emergent Biosolutions' Plasma Collection Center in Winnipeg, Canada",2015-05-28 07:20:00-04:00,EBS,neutral
402829.0,"Pentagon Confirms Inadvertent Transfer of Samples Containing Live Anthrax, Says No Risk to Public -Reuters",2015-05-27 15:14:00-04:00,EBS,negative
402830.0,S-3ASR Emergent Biosolutions Files Automatic Mixed Shelf Registration,2015-05-22 14:51:00-04:00,EBS,neutral
402831.0,Emergent BioSolutions Signs Long-Term Manufacturing Agreement With Prometic Life Sciences,2015-05-19 07:05:00-04:00,EBS,positive
402832.0,"Emergent BioSolutions, Prometic Life Sciences Agree To Long-Term Manufacturing Agreement",2015-05-19 07:04:00-04:00,EBS,positive
402833.0,"Emergent BioSolutions Reports Q1 Loss $0.57 Vs Est Loss $0.44, Sales $63.6M Vs Est $56.50M",2015-05-07 16:29:00-04:00,EBS,negative
402834.0,Emergent BioSolutions Announces FDA Approval of IXINITY for Hemophilia B,2015-04-30 07:09:00-04:00,EBS,positive
402835.0,Evolva Completes Transfer of EV-035 to Emergent BioSolutions; Triggers $4M Payment,2015-04-23 04:33:00-04:00,EBS,neutral
402836.0,Emergent Biosoulutions Announces FDA Approval of Anthrasil,2015-03-25 07:02:00-04:00,EBS,positive
402837.0,"Emergent BioSolutions Awarded $31 Million Contract for Advanced Development of NuThrax, a Next Generation Anthrax Vaccine",2015-03-24 07:01:00-04:00,EBS,positive
402838.0,"Emergent BioSolutions Signs Agreements With Oxford University, GlaxoSmithKline, and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate",2015-03-16 07:05:00-04:00,EBS,positive
402839.0,Emergent BioSolutions and MorphoSys Initiate Phase 1 Clinical Study to Evaluate the Novel Oncology Immunotherapeutic MOR209/ES414 for Prostate Cancer,2015-03-09 07:00:00-04:00,EBS,negative
402840.0,"MorphoSys Emergent BioSolutions, Initiate Phase 1 Clinical Study to Evaluate  MOR209/ES414 for Prostate Cancer",2015-03-09 04:37:00-04:00,EBS,negative
402841.0,Morning Market Losers,2015-03-06 09:51:00-05:00,EBS,negative
402842.0,"After-Hours Movers Led By Calithera Biosciences, Violin Memory & PowerSecure",2015-03-05 17:49:00-05:00,EBS,neutral
402843.0,"Emergent Biosolutions Reports Q4 Adj. EPS $0.75 vs. $0.69, Rev. $148M vs. Est. $147M; Stock Trending Down 0.81% To $29.24",2015-03-05 16:52:00-05:00,EBS,neutral
402844.0,Emergent BioSolutions Sees Q1 Sales $90.0M-105.0M vs $147.75M Est,2015-01-11 16:17:00-05:00,EBS,neutral
402845.0,Emergent BioSolutions Sees FY2015 Sales $510.0M-540.0M vs $486.25M Est,2015-01-11 16:16:00-05:00,EBS,neutral
402846.0,Emergent BioSolutions Sees FY2014 Sales $445.0M-450.0M vs $449.87M Est,2015-01-11 16:15:00-05:00,EBS,neutral
402847.0,"Emergent Reports Submission of FDA Application for Post-Exposure Prophylaxis, Looking for Expanded Biothrax Label",2014-11-10 07:15:00-05:00,EBS,neutral
402848.0,"Emergent BioSolutions Awarded $29M 5-Year Contract To Develop A Dry Formulation Of NuThrax, A Next Generation Anthrax Vaccine",2014-09-08 13:54:00-04:00,EBS,positive
402849.0,MorphoSys And Emergent BioSolutions Sign License Agreement to Co-Develop And Commercialize Prostate Cancer Drug Candidate ES414   ,2014-08-19 17:47:00-04:00,EBS,negative
402850.0,"Emergent Biosolutions, Inc. Reports Q2 EPS of $0.13 Which May Not Compare $0.32 Est; Revenue of $110.30M Which May Not Compare $109.25M Est",2014-08-07 16:28:00-04:00,EBS,neutral
402851.0,Emergent BioSolutions Applices For to FDA for License for Anthra Immune Globulin Intravenous,2014-08-07 07:02:00-04:00,EBS,positive
402852.0,UPDATE: CDC Reports Has Identified 86 Potential Exposures to Live Anthrax Bacteria,2014-06-20 10:32:00-04:00,EBS,negative
402853.0,Reuters Reports CDC Says As Many As 75 Of Its Scientists May Have Been Accidentally Exposed To Live Anthrax,2014-06-19 15:27:00-04:00,EBS,negative
402854.0,"Summer Street Initiates Coverage on Emergent Biosolutions, Inc. at Buy, Announces $35.00 PT",2014-05-15 09:46:00-04:00,EBS,neutral
402855.0,"Emergent Biosolutions, Inc. Sees FY2014 Sales $415.0M-445.0M vs $439.20M Est",2014-05-08 16:24:00-04:00,EBS,neutral
402856.0,"Emergent Biosolutions, Inc. Sees Q2 Sales $95.0M-110.0M vs $119.55M Est",2014-05-08 16:24:00-04:00,EBS,neutral
402857.0,"Emergent Biosolutions, Inc. Reports Q1 EPS of $(0.55) Which May Not Compare $(0.14) Est; Revenue of $53.90M Which May Not Compare $57.30M Est",2014-05-08 16:23:00-04:00,EBS,neutral
402858.0,US Stock Futures Up Ahead Of Earnings,2014-04-21 07:31:00-04:00,EBS,neutral
402859.0,Emergent BioSolutions Receives FDA Orphan Drug Designation for BioThrax for Post-Exposure Prophylaxis of Anthrax Disease ,2014-04-21 07:04:00-04:00,EBS,neutral
402860.0,Emergent BioSolutions Successfully Closes Pivotal Clinical Study Support Expanded Indication for BioThrax,2014-04-16 07:22:00-04:00,EBS,positive
402861.0,"Emergent Biosolutions, Inc. Sees Q1 Sales $45.0M-55.0M",2014-03-06 16:12:00-05:00,EBS,neutral
402862.0,"Emergent Biosolutions, Inc. Reports Q1 EPS of $0.41 vs $0.36 Est; Revenue of $98.10M vs $93.83M Est",2014-03-06 16:07:00-05:00,EBS,neutral
402863.0,Emergent BioSolutions Completes Acquisition Of Cangene,2014-02-21 11:20:00-05:00,EBS,neutral
402864.0,Emergent BioSolutions Announces Completion of $250M Convertible Senior Notes Offering,2014-01-29 16:52:00-05:00,EBS,neutral
402865.0,Emergent BioSolutions Announces $35M Option Exercised by Initial Purchasers of Company's Convertible Senior Notes ,2014-01-27 07:06:00-05:00,EBS,neutral
402866.0,Emergent BioSolutions Announces Positive Phase 1b Otlertuzumab Results in Combination with Rituximab in People with CLL ,2013-12-10 07:13:00-05:00,EBS,positive
402867.0,Emergent BioSolutions Presents Positive Interim Phase 2 Data Evaluating Otlertuzumab in Combination with Bendamustine in People with Relapsed Chronic Lymphocytic Leukemia ,2013-12-09 07:05:00-05:00,EBS,positive
402868.0,"Emergent Biosolutions, Inc. Reports Q3 EPS of $0.36 vs $0.21 Est; Revenue of $89.10M vs $79.13M Est",2013-11-07 16:25:00-05:00,EBS,neutral
402869.0,"Emergent Biosolutions, Inc. Sees Q3 Sales $70.0M-80.0M vs $81.14M Est",2013-08-05 16:25:00-04:00,EBS,neutral
402870.0,"Emergent Biosolutions, Inc. Reports Q2 EPS of $0.29 vs $0.21 Est",2013-08-05 16:25:00-04:00,EBS,neutral
402871.0,Emergent Biosolutions Close Purchase of Healthcare Protective Products Unit from Bracco,2013-08-02 07:07:00-04:00,EBS,neutral
402872.0,Emergent BioSolutions Advances Program Supporting Licensure of a Post-Exposure Prophylaxis Indication for BioThrax ,2013-07-10 16:12:00-04:00,EBS,positive
402873.0,Emergent BioSolutions Receives Paul-Ehrlich-Institut Approval to Market BioThrax in Germany ,2013-07-01 07:12:00-04:00,EBS,positive
402874.0,"Emergent Biosolutions, Inc. Reports Q1 EPS of $(0.22) vs $(0.14) Est; Revenue of $43.10M vs $46.17M Est",2013-05-02 16:49:00-04:00,EBS,neutral
402875.0,"Emergent Biosolutions Moves Higher on Speculation Letter Sent to President Believed to Contain Anthrax, Other Reports Say it's Ricin",2013-04-17 11:32:00-04:00,EBS,neutral
402876.0,"Janney Capital Initiates Coverage on Emergent Biosolutions, Inc. at Buy, Announces $20.00 PT",2013-04-10 16:33:00-04:00,EBS,neutral
402877.0,A Peek Into The Market Before The Trading Starts,2013-04-05 07:17:00-04:00,EBS,neutral
402878.0,Emergent BioSolutions to Expand Front Line CLL Clinical Trial of TRU-016 and Rituximab ,2013-04-05 07:02:00-04:00,EBS,positive
402879.0,"Emergent Biosolutions, Inc. Sees FY2013 Sales $290.0M-310.0M vs $300.10M Est",2013-03-07 16:04:00-05:00,EBS,neutral
402880.0,"Emergent Biosolutions, Inc. Sees Q1 Sales $40.0M-50.0M vs $59.90M Est",2013-03-07 16:04:00-05:00,EBS,neutral
402881.0,"Emergent Biosolutions, Inc. Reports Q4 EPS of $0.45, Inline; Revenue of $94.60M",2013-03-07 16:04:00-05:00,EBS,neutral
402882.0,Emergent BioSolutions Announces Data from Phase IIb Trial for MVA85A Published in The Lancet ,2013-02-04 07:04:00-05:00,EBS,neutral
402883.0,Emergent BioSolutions Begins Phase 2 Clinical Trial for Anthrax Vaccine NuThrax ,2013-01-17 07:05:00-05:00,EBS,neutral
402884.0,"Emergent Biosolutions Looking for FY12 Net Income $21-24M (Including $9.6M Charge), Sales $280-284M; Sees FY13 Adj. Net Income $20-30M, Sales $290-310M",2013-01-07 07:55:00-05:00,EBS,neutral
402885.0,Emergent Receives Orphan Medicinal Product Designation from European Commission for TRU-016 for CLL ,2013-01-02 07:06:00-05:00,EBS,neutral
402886.0,Emergent Biosolutions Secures Exclusive US Commercial Rights to NextGen Pandemic Influenza Vaccine Candidate,2012-12-28 12:44:00-05:00,EBS,positive
402887.0,Top 4 NYSE Stocks In The Biotechnology Industry With The Highest ROA,2012-12-07 03:44:00-05:00,EBS,positive
402888.0,Emergent BioSolutions Names Robert G. Kramer CFO,2012-11-19 07:18:00-05:00,EBS,neutral
402889.0,Emergent Biosolutions Reports Q3 EPS $0.18 vs $0.14 Est; Revenues $66.6M vs $68.49M Est,2012-11-01 07:25:00-04:00,EBS,neutral
402890.0,Emergent BioSolutions Initiates Phase 1b Study of TRU-016 in Combination with  Rituximab ,2012-10-31 07:18:00-04:00,EBS,neutral
402891.0,Top 4 NYSE Stocks In The Biotechnology Industry With The Highest Revenue Estimates,2012-10-24 03:27:00-04:00,EBS,positive
402892.0,Emergent Biosolutions Reports Q2 EPS $0.21 vs $0.23 Est; Revenues $70.4M vs $76.82M Est,2012-08-02 16:21:00-04:00,EBS,neutral
402893.0,"UPDATE: Piper Jaffray Initiates Emergent BioSolutions with Overweight, $21 PT on Post-BioThrax Potential  ",2012-06-11 10:58:00-04:00,EBS,negative
402894.0,"Piper Jaffray Initiates Emergent BioSolutions at Overweight, $21 PT",2012-06-11 06:04:00-04:00,EBS,negative
402895.0,Emergent BioSolutions Announces Stock Repurchase Program of up to $35M   ,2012-05-21 07:00:00-04:00,EBS,neutral
402896.0,Emergent Biosolutions Reports Q1 EPS $-0.02 May Not Compare to $-0.15 Est; Revenues $50.3M vs $47.32M Est,2012-05-03 16:44:00-04:00,EBS,neutral
402897.0,"European morning wrap:  Rule, Britannia!, sterling king of the heap",2012-04-18 06:51:00-04:00,EBS,neutral
402898.0,"European morning wrap:  Can't beat a bit of consolidation, is what I say",2012-03-28 06:53:00-04:00,EBS,neutral
402899.0,European morning wrap:  Market in consolidative mood this morning,2012-03-27 06:39:00-04:00,EBS,neutral
402900.0,Emergent Biosolutions Reports Q4 EPS $0.78 vs $0.72 Est; Revenues $107.90M vs $109.32M Est,2012-03-08 16:02:00-05:00,EBS,neutral
402901.0,"European morning wrap:  Yipeeeeeee, risk on!!!",2012-03-08 06:34:00-05:00,EBS,negative
402902.0,European morning wrap: Helter skelter….NOT.  Is it Monday?,2012-03-05 06:29:00-05:00,EBS,neutral
402903.0,Weekly Traders Homework: Frustrated Bears,2012-01-29 20:15:00-05:00,EBS,negative
402904.0,Emergent BioSolutions Subsidiary Announces Contract Modification,2012-01-17 14:16:00-05:00,EBS,neutral
402905.0,"Financial Breakfast: Morning News Summary for January 9, 2012",2012-01-09 07:26:00-05:00,EBS,neutral
402906.0,UPDATE: Emergent BioSolutions Expects 2012 Revs $280-$300M vs $309M Est ,2012-01-09 07:03:00-05:00,EBS,neutral
402907.0,Emergent BioSolutions Expects 2012 Revs $280-$300M vs $309M Est,2012-01-09 07:02:00-05:00,EBS,neutral
402908.0,A Peek Into The Market Before The Trading Starts,2011-12-28 07:59:00-05:00,EBS,neutral
402909.0,Emergent Announces Plans for TRU-016 Program Following Termination of Collaboration with Abbott   ,2011-12-28 07:00:00-05:00,EBS,neutral
402910.0,Emergent Initiates Phase 2 Study of TRU-016 in Combination with Bendamustine in Patients with Relapsed Chronic Lymphocytic Leukemia   ,2011-12-28 07:00:00-05:00,EBS,neutral
402911.0,Emergent BioSolutions Announces Fuad El-Hibri to Retire as CEO,2011-12-21 14:00:00-05:00,EBS,neutral
402912.0,"European morning wrap: Risk off, innit bro",2011-12-12 07:25:00-05:00,EBS,negative
402913.0,Emergent BioSolutions Receives Orphan Drug Designation for Its TRU-016 Protein Therapeutic for the Treatment of Chronic Lymphocytic Leukemia   ,2011-12-01 07:04:00-05:00,EBS,neutral
402914.0,"WABCO Marks Another Industry First for Advanced Safety Technology in China as Part of Contract With Yutong,",2011-11-29 07:02:00-05:00,EBS,positive
402915.0,Emergent BioSolutions Initiates Pivotal Clinical Trial Evaluating a Three-Dose BioThrax Regimen for Post-Exposure Prophylaxis   ,2011-11-17 06:53:00-05:00,EBS,neutral
402916.0,Emergent BioSolutions Reports Q3 EPS $0.04 vs $0.10 Est; Revenues $58.80M vs $63.59M Est		,2011-11-03 16:07:00-04:00,EBS,neutral
402917.0,Top 4 NYSE Stocks In The Biotechnology Industry With The Highest ROE,2011-10-24 04:29:00-04:00,EBS,positive
402918.0,UPDATE: Wedbush Lowers PT on EBS to $31,2011-10-04 08:39:00-04:00,EBS,negative
402919.0,Wedbush Lowers PT on Emergent BioSolutions to $31,2011-10-04 06:44:00-04:00,EBS,negative
402920.0,Emergent BioSolutions Receives Award to Supply 44.75 Million Doses of BioThrax to U.S. Government over Five Years,2011-10-03 07:01:00-04:00,EBS,positive
402921.0,"Progress Software Reports Positive Quarter, Poor Guidance",2011-09-27 16:40:00-04:00,EBS,positive
402922.0,European Morning Wrap: FX Market Labours on Labor Day,2011-09-05 06:23:00-04:00,EBS,neutral
402923.0,Results of Emergent BioSolutions Phase 1a Study on Adjuvanted BioThrax Anthrax Vaccine Published in the Journal Vaccine  ,2011-08-26 06:53:00-04:00,EBS,neutral
402924.0,Emergent Announces Initiation of a Phase 1b/2 Study of TRU-016 in Combination with Rituximab and Bendamustine in Subjects with Relapsed - Indolent Lymphoma   ,2011-08-17 07:02:00-04:00,EBS,neutral
402925.0,Emergent BioSolutions Reports Q2 EPS $0.39 vs $0.34 Est; Revenues $88.1M vs $84.20M Est        ,2011-08-04 16:16:00-04:00,EBS,neutral
402926.0,Progress Software Roll Over in the After-Hours,2011-06-28 16:53:00-04:00,EBS,positive
402927.0,"Emergent BioSolutions' Investigational Anthrax Vaccine, NuThrax, Granted Fast Track Designation   ",2011-06-09 14:40:00-04:00,EBS,positive
402928.0,A Peek Into The Market Before The Trading Starts,2011-06-06 07:30:00-04:00,EBS,neutral
402929.0,Emergent BioSolutions Acquires Late-Stage Monoclonal Antibody Cancer Therapy from TenX BioPharma ,2011-06-06 07:04:00-04:00,EBS,negative
402930.0,UPDATE: J.P. Morgan Raises PT on Emergent BioSolutions to $35,2011-05-27 08:02:00-04:00,EBS,neutral
402931.0,JP Morgan Raises PT On Emergent BioSolutions To $35,2011-05-27 07:00:00-04:00,EBS,positive
402932.0,Emergent Biosolutions Ticks over 15% Higher on Anticipated Government Agreement,2011-05-26 13:20:00-04:00,EBS,positive
402933.0,"Top Percentage Gainers and Losers as of 12pm 5/09/11 (SCEI, FFHL ROSE, SMI, DTG, HTZ, SYY, CERS, LFT, ZRAN, OXGN, MOBI, GKK, EBS, TSN)",2011-05-09 12:06:00-04:00,EBS,negative
402934.0,Biotech/ Biodefense Sector Trading Alert,2011-05-05 13:36:00-04:00,EBS,positive
402935.0,U.S. Government Expands BioThrax Procurement Contract to 17.92M Doses from 14.5M Increasing Contract Value by up to $101 Million (EBS),2011-05-02 16:42:00-04:00,EBS,positive
402936.0,Biotech/ Biodefense Stock Trading Alert; Emergent Biosolutions (NYSE: EBS) Hits 52 Week High,2011-04-14 09:00:00-04:00,EBS,positive
402937.0,Biotech/ Biodefense Stock Trading Alert; Emergent Biosolutions (NYSE: EBS) Hits 52 Week High,2011-04-14 09:00:00-04:00,EBS,positive
402938.0,Emergent BioSolutions Hits 52-Week High (EBS),2011-04-13 11:10:00-04:00,EBS,neutral
402939.0,Biotech/ Biodefense Sector Trading Alert,2011-04-08 12:14:00-04:00,EBS,positive
402940.0,"Biodefense Stocks/ Homeland Defense Stock Alert; Dynasil Corporation trading at $6.26, up 2.50 (66.49%)",2011-03-23 14:17:00-04:00,EBS,positive
402941.0,Biodefense Stocks Snapshot,2011-03-22 14:08:00-04:00,EBS,neutral
402942.0,J.P. Morgan Comments On Uneventful 4Q10 Results For Emergent BioSolutions,2011-03-11 08:48:00-05:00,EBS,neutral
402943.0,Emergent BioSolutions Announces that European Parliament Expresses Support for Rapid Development of New TB Vaccine  ,2011-02-25 10:52:00-05:00,EBS,positive
402944.0,Zacks #5 Rank Additions for Thursday - Tale of the Tape,2011-01-13 08:46:00-05:00,EBS,neutral
402945.0,Zacks #5 Rank Additions for Thursday - Tale of the Tape,2011-01-13 08:14:00-05:00,EBS,neutral
402946.0,First California to Acquire Division of Palm Desert National Bank  ,2010-12-30 15:30:00-05:00,EBS,neutral
402947.0,Emergent BioSolutions Starts Phase I Clinical Trial for Third Generation Anthrax Vaccine ,2010-12-27 16:32:00-05:00,EBS,neutral
402948.0,Can Pharmathene Go From $2 To $20? Seeking Alpha's James Altucher Investigates,2010-10-15 11:03:00-04:00,EBS,neutral
402949.0,WellPoint Appoints Lori Beer as Executive Vice President ,2010-10-08 13:08:00-04:00,EBS,neutral
402950.0,Emergent BioSolutions Awarded Contract Valued at up to $186.6 Million (EBS),2010-09-17 13:16:00-04:00,EBS,positive
402951.0,Accenture Clinches Defense Order - Analyst Blog,2010-09-08 17:48:00-04:00,EBS,positive
402952.0, Trubion Pharmaceuticals Announces Early Termination of HSR Waiting Period,2010-09-08 16:05:00-04:00,EBS,neutral
402953.0,Emergent BioSolutions Announces Early Termination of HSR Waiting Period for Its Acquisition of Trubion Pharmaceuticals,2010-09-08 16:02:00-04:00,EBS,neutral
402954.0,Trubion Pharma Trims Loss  - Analyst Blog,2010-08-18 15:37:00-04:00,EBS,negative
402955.0,"Benzinga’s Top Pre-Market NASDAQ Gainers (UNCA, PRXI, TRBN, VECO)",2010-08-13 09:19:00-04:00,EBS,positive
402956.0,"Top 5 Small-Cap Stocks In The Biotechnology Industry With The Highest Return On Equity (OMPI, MRX, AOB, EBS, SSRX)",2010-06-03 07:08:00-04:00,EBS,positive
402957.0,"Benzinga’s Top Downgrades (SWM , COGT, PRO, CNP, EBS)",2010-05-06 10:01:00-04:00,EBS,positive
402958.0,Should You Buy the Big Winners of 2009?,2010-01-05 17:04:00-05:00,EBS,positive
402959.0,The Forex Marketplace,2009-12-14 12:22:00-05:00,EBS,neutral
402960.0,J.P.Morgan’s View on Emergent BioSolutions Inc. (NYSE: EBS) ,2009-12-04 09:43:00-05:00,EBS,neutral
402961.0,"Cramer talks about AEPI, GRA, TKLC, LVS, WYNN, EBS",2009-10-09 05:30:00-04:00,EBS,neutral
